Douglas S M Iaboni1, Yueh-Yun Chi2, Yeonil Kim2, Jeffrey S Dome3, Conrad V Fernandez4. 1. Faculty of Medicine, Dalhousie Medical School, Dalhousie University, Halifax, Canada. 2. Department of Biostatistics, University of Florida, Gainesville, Florida. 3. Children's National Medical Center, Washington, DC. 4. Department of Pediatrics, IWK Health Centre, Dalhousie University, Halifax, Canada.
Abstract
BACKGROUND: Wilms tumor (WT) is the most common renal tumor in children. We describe the outcomes for patients with WT that metastasized to bone (WTBM) to assist in decision making for these uncommon patients. PROCEDURE: We retrospectively reviewed the research records of patients identified with WTBM from the National Wilms Tumor Study (NWTS 1-5) database. We then related overall survival (OS) to histology, chemotherapy, radiation therapy to bone, location of metastasis, and when bone metastasis presented. RESULTS: Thirty-eight of 8609 patients enrolled on NWTS 1-5 (0.44%) developed bone metastasis. Bone metastasis most commonly first occurred at progression or relapse (29/38, 76%). Five of thirty-eight survived (13%) with the 5-year OS following presentation of bone metastasis of 14.3% (95% CI: 2.7-25.8%). The primary cause of death was tumor (29/33, 88%). Of those who died, the median survival time was 10.9 months (range 0.49-61.4). Four of nine (44%) patients presenting at diagnosis and 3% (1/29) of patients presenting in progression or relapse survived (P = 0.0075). Nineteen percent (5/26) of patients with favorable histology and 0% (0/12) with anaplastic histology survived (P = 0.16). Of the five survivors, median follow-up was 14 years (range 6.7-23.8). Radiation to metastatic bone sites was recorded in three of five survivors. No consistent chemotherapeutic approach appeared to be associated with disease outcome. CONCLUSION: Bone metastasis is rare in patients with WT, occurring more commonly in progression or relapse than at initial diagnosis. Patients with WTBM have poor prognosis. We could not identify a consistent chemotherapeutic strategy associated with survival.
BACKGROUND:Wilms tumor (WT) is the most common renal tumor in children. We describe the outcomes for patients with WT that metastasized to bone (WTBM) to assist in decision making for these uncommon patients. PROCEDURE: We retrospectively reviewed the research records of patients identified with WTBM from the National Wilms Tumor Study (NWTS 1-5) database. We then related overall survival (OS) to histology, chemotherapy, radiation therapy to bone, location of metastasis, and when bone metastasis presented. RESULTS: Thirty-eight of 8609 patients enrolled on NWTS 1-5 (0.44%) developed bone metastasis. Bone metastasis most commonly first occurred at progression or relapse (29/38, 76%). Five of thirty-eight survived (13%) with the 5-year OS following presentation of bone metastasis of 14.3% (95% CI: 2.7-25.8%). The primary cause of death was tumor (29/33, 88%). Of those who died, the median survival time was 10.9 months (range 0.49-61.4). Four of nine (44%) patients presenting at diagnosis and 3% (1/29) of patients presenting in progression or relapse survived (P = 0.0075). Nineteen percent (5/26) of patients with favorable histology and 0% (0/12) with anaplastic histology survived (P = 0.16). Of the five survivors, median follow-up was 14 years (range 6.7-23.8). Radiation to metastatic bone sites was recorded in three of five survivors. No consistent chemotherapeutic approach appeared to be associated with disease outcome. CONCLUSION: Bone metastasis is rare in patients with WT, occurring more commonly in progression or relapse than at initial diagnosis. Patients with WTBM have poor prognosis. We could not identify a consistent chemotherapeutic strategy associated with survival.
Authors: D M Green; N E Breslow; J B Beckwith; J Z Finklestein; P Grundy; P R Thomas; T Kim; S Shochat; G Haase; M Ritchey; P Kelalis; G J D'Angio Journal: J Clin Oncol Date: 1998-12 Impact factor: 44.544
Authors: Christopher Mitchell; Kathy Pritchard-Jones; Rosemary Shannon; Carolyn Hutton; Suzanne Stevens; David Machin; John Imeson; Anna Kelsey; Gordan M Vujanic; Peter Gornall; Jenny Walker; Roger Taylor; Pat Sartori; Juliet Hale; Gill Levitt; Boo Messahel; Helen Middleton; Richard Grundy; Jon Pritchard Journal: Eur J Cancer Date: 2006-08-10 Impact factor: 9.162
Authors: Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: Marcio Malogolowkin; Cecilia A Cotton; Daniel M Green; Norman E Breslow; Elizabeth Perlman; James Miser; Michael L Ritchey; Patrick R M Thomas; Paul E Grundy; Giulio J D'Angio; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Milton Donaldson; Robert Weetman; Max J Coppes; Patricia Shearer; Peter Coccia; Morris Kletzel; Roger Macklis; Gail Tomlinson; Vicki Huff; Robert Newbury; Douglas Weeks Journal: Pediatr Blood Cancer Date: 2008-02 Impact factor: 3.167
Authors: Tasnim Chagtai; Christina Zill; Linda Dainese; Jenny Wegert; Suvi Savola; Sergey Popov; William Mifsud; Gordan Vujanić; Neil Sebire; Yves Le Bouc; Peter F Ambros; Leo Kager; Maureen J O'Sullivan; Annick Blaise; Christophe Bergeron; Linda Holmquist Mengelbier; David Gisselsson; Marcel Kool; Godelieve A M Tytgat; Marry M van den Heuvel-Eibrink; Norbert Graf; Harm van Tinteren; Aurore Coulomb; Manfred Gessler; Richard Dafydd Williams; Kathy Pritchard-Jones Journal: J Clin Oncol Date: 2016-07-18 Impact factor: 44.544